Search

A patent has been issued for an efficient cell culture system for hepatitis C virus genotype 6A by inventors from Hvidovre Hospital in Denmark. Genotype 6 of the virus is prevalent in East- and Southeast Asia and is associated with an increased risk of liver cancer among Asian patients with cirrhosis. The patent focuses on nucleotide sequences that encode HCV genotype 6a, allowing for research on viral pathogenesis, drug efficacy, resistance, and vaccine development. [Extracted from the article]

This document is a patent application for methods of treating and ameliorating T cell-related diseases using a formulation or product containing sunitinib or its salts or formulations. The diseases and conditions that can be treated include autoimmune diseases, organ transplant rejection, graft-versus-host disease, and B cell chronic lymphocytic leukemia. The formulation can be administered through various methods such as inhalation, intravenous injection, or topical application. The patent application provides detailed descriptions of the methods and formulations. [Extracted from the article]

The patent application titled "Cell Conversion" discusses a method for converting one type of cell into another using self-replicating RNA (repRNA). This method allows for prolonged gene expression without the need for repeated transfection or genetic modification. The inventors have demonstrated that this method is more efficient than other methods using lentivirus or mRNA. The repRNA can be used to convert cells in vitro, in vivo, or ex vivo, and the patent application also includes claims for the repRNA composition and its use in medicine. [Extracted from the article]

A patent application titled "Methods for Treating HCV" has been published online by the US Patent and Trademark Office. The patent application, filed by AbbVie Inc., describes methods for treating Hepatitis C Virus (HCV) infection using direct acting antiviral agents (DAAs). The treatment involves administering at least two DAAs to patients for a duration of no more than 12 weeks, without the use of interferon or ribavirin. The methods aim to provide a sustained virological response (SVR) and improve the effectiveness of HCV treatment. [Extracted from the article]

A patent application has been filed for a method of treating Zika virus infection using a quercetin-containing composition, along with vitamin B3, vitamin C, and a folate compound. The method aims to address the need for effective treatments for Zika virus infection, which can cause symptoms such as fever, rash, and conjunctivitis, and has been associated with fetal loss and microcephaly in pregnant women. The composition may also be used to prevent or reduce the risk of microcephaly in fetuses. The patent application does not specify any assigned company or institution. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the identification of a mimotope of a complex gp41 Human Immunodeficiency Virus (HIV) epitope related to a non-structural protein of Hepacivirus that has been previously implicated in Kawasaki disease. The study focuses on a highly mutated VH1-02 antibody called 6F5, which has the ability to mediate Ab dependent cell cytotoxicity (ADCC). The researchers sought to identify a protein target for vaccine development and found that the 76Canc germline antibody, which targets the same epitope as 6F5, specifically recognized a peptide sequence similar to a non-structural protein of Hepacivirus. However, the study also showed little risk of autoimmune targeting or inflammation similar to Kawasaki disease, suggesting caution in the development of such peptides for vaccination. [Extracted from the article]

A patent application titled "Advantageous Anti-HCV Combination Therapy" has been published by the US Patent and Trademark Office. The application, filed by Atea Pharmaceuticals Inc., discusses the development of therapies for Hepatitis C (HCV) infection. It provides background information on HCV, its impact on liver disease, and the role of RNA polymerase in viral replication. The application discusses a combination therapy involving Compound 1, a pan-genotypic NS5B polymerase inhibitor, and Compound 2, an NS5A inhibitor. This combination has shown promising results in treating HCV infections, including different genotypes and subtypes, and has the potential to achieve a sustained viral response in as little as 6 weeks. The therapy can be administered orally or parenterally and has the advantage of limiting the emergence of drug resistance. [Extracted from the article]

A recent report from the Chinese Academy of Sciences highlights the potential of the Chinese tree shrew as an experimental model for biomedical research. The researchers used metatranscriptomic sequencing to analyze samples from healthy tree shrews and identified eight mammalian viruses, including the first recorded presence of rotavirus in tree shrews. Three of the viruses were found to be novel, while others showed high similarity to known viral strains. The study emphasizes the need for further research into the potential for cross-species transmission of these viruses. [Extracted from the article]

A patent application has been submitted by AbbVie Inc. for methods of treating HCV infection. The methods involve administering at least two direct acting antiviral agents (DAAs) to patients for a duration of no more than 12 weeks. The treatment does not include interferon or ribavirin, and the DAAs can include compounds such as sofosbuvir. The goal of the treatment is to achieve a sustained virological response (SVR) in the majority of patients. The patent application provides specific dosing schemes and frequencies for the administration of the DAAs. [Extracted from the article]

Researchers at the University of the Basque Country have published a study on the implementation of computational models in drug discovery against the Flaviviridae family, which includes the Hepacivirus. The study highlights the importance of computational chemistry in developing new drugs and treatments for diseases caused by this family of RNA viruses. The perturbation theory machine learning method has shown promising results in handling and processing large datasets, reducing false positives and achieving high accuracy and reliability. The researchers conclude that these models can serve as valuable tools in drug discovery efforts and the development of new treatments for Flaviviridae family diseases. [Extracted from the article]

A new report from Emory University discusses the role of B cells and their antibodies in the clearance of acute HCV infection. The study utilized a rodent model of HCV infection and found that B cells and their antibodies were crucial for viral resolution. The researchers also found that the presence of CD8+ T cells was necessary for the clearance of the virus. These findings suggest that HCV vaccine regimens should aim to elicit both robust antibody and T cell responses for optimal protective efficacy. [Extracted from the article]

A recent report from researchers at Yunnan University of Chinese Medicine explores the pathogenesis of cardiovascular disease caused by Flaviviridae viruses. The study highlights the diverse range of severe human pathologies associated with these viruses, including hepatitis, vascular shock syndrome, encephalitis, acute flaccid paralysis, and adverse fetal outcomes. Despite the significant cardiovascular compromise caused by Flaviviridae infections, the mechanisms and cardiovascular sequelae remain relatively underexplored. The researchers aim to construct a theoretical framework to better understand the pathogenesis of Flaviviridae-induced cardiovascular injury and identify potential therapeutic approaches. [Extracted from the article]

A patent application has been filed for methods of treating Hepatitis C Virus (HCV) infection. The methods involve administering at least two direct-acting antiviral agents (DAAs) to patients with HCV infection, including those with chronic kidney disease (CKD) or co-infection with HIV. The treatment does not include interferon or ribavirin and lasts for a duration of 8 or 12 weeks. The combination of DAAs used in the treatment includes Compound 1 and Compound 2. The methods aim to provide a sustained virological response (SVR) and avoid the side effects associated with interferon or ribavirin. [Extracted from the article]

A patent application has been submitted for a method to detect respiratory infections in dogs, specifically focusing on Canine Infectious Respiratory Disease Complex (CIRDC). The method involves using a lateral flow device to bind to target analytes associated with the respiratory condition and produce a detectable signal. This can help determine if a dog has the respiratory condition or immunity to it. The application aims to address the need for early detection and intervention to reduce the progression and transmission of the disease. The patent application provides detailed information on the specific pathogens and antigens associated with CIRDC that can be targeted in the analysis. [Extracted from the article]

Gamal Shiha talks to Gary Humphreys about how Egypt went from being one of the highest hepatitis C-prevalence countries in the world to being on the brink of eliminating the disease., ((c) 2024 The authors; licensee World Health Organization.)

A recent preprint abstract discusses the mapping of glycoprotein structure in the Flaviviridae family of viruses. The study aims to understand the role of glycoproteins in viral membrane fusion and their impact on host range, tissue tropism, and pathogenesis. The researchers used phylogenetic analyses and protein structure prediction to examine glycoproteins across the Flaviviridae family. They discovered class-II fusion systems in most species, but the E1E2 glycoproteins of hepaci-, pegi-, and pestiviruses were structurally distinct and potentially represented a novel class of fusion mechanism. The study provides insights into the evolutionary history and diversity of the Flaviviridae family. [Extracted from the article]

A patent application by AbbVie Inc. describes methods for treating Hepatitis C Virus (HCV) infection. The methods involve administering at least two direct acting antiviral agents (DAAs) to patients for a duration of no more than 12 weeks. The treatment excludes the use of interferon and ribavirin, which can cause side effects. The goal of the treatment is to achieve a sustained virological response (SVR) in the majority of patients. The patent application provides specific dosing schemes and combinations of DAAs that can be used. [Extracted from the article]

A recent preprint abstract discusses a comprehensive survey of conserved RNA secondary structures in the full-genome alignment of the Hepatitis C Virus (HCV). The study aims to identify which RNA secondary structures in the HCV genome are conserved due to functional requirements. The results indicate that certain regions of the genome, such as the core coding region and the NS5A and NS5B regions, contain conserved secondary structure elements, suggesting functionality at the RNA level. However, other regions of the genome contain less conserved structures. The study provides a complete description of these conserved RNA secondary structures and offers full-genome alignments of all branches of Hepacivirus C. Please note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent preprint abstract discusses the discovery of new endogenous viral elements (EVEs) in vertebrate genomes. The study used ElasticBLAST on the Google Cloud Platform to search for EVEs across vertebrates and found evidence of EVEs belonging to several viral families, including Chuviridae, Paramyxoviridae, Nairoviridae, and Benyviridae. Additionally, an EVE from the Hepacivirus genus of flaviviruses was found with orthology across murine rodents. The findings increase the diversity of non-retroviral EVEs in vertebrates by 44% and provide insights into the natural history and evolution of viruses. It is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

Body weight loss, hepatocyte infection frequency, viral evolution, T-cell recruitment to the liver, liver inflammation and the capacity to develop liver fibrosis varied among infected CC strains." Keywords: Digestive System Diseases and Conditions; Flaviviridae; Flaviviridae Infections; Gastroenterology; Genetics; Health and Medicine; Hepacivirus; Hepatitis C Virus; Hepatitis Viruses; Hepatology; Liver Cirrhosis; Liver Diseases and Conditions; Liver Fibrosis; RNA Viruses; Risk and Prevention; Viral; Virology EN Digestive System Diseases and Conditions Flaviviridae Flaviviridae Infections Gastroenterology Genetics Health and Medicine Hepacivirus Hepatitis C Virus Hepatitis Viruses Hepatology Liver Cirrhosis Liver Diseases and Conditions Liver Fibrosis RNA Viruses Risk and Prevention Viral Virology 607 607 1 08/21/23 20230821 NES 230821 2023 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Investigators publish new report on hepatitis C virus. [Extracted from the article]

Keywords: Kolkata; India; Asia; Digestive System Diseases and Conditions; Drug Development; Drug Molecules; Drugs and Therapies; Gastroenterology; Health and Medicine; Hepacivirus; Hepatitis; Hepatitis C Virus; Hepatology; Infectious Diseases and Conditions; Liver Diseases and Conditions; RNA Viruses; Risk and Prevention; Viral; Virology EN Kolkata India Asia Digestive System Diseases and Conditions Drug Development Drug Molecules Drugs and Therapies Gastroenterology Health and Medicine Hepacivirus Hepatitis Hepatitis C Virus Hepatology Infectious Diseases and Conditions Liver Diseases and Conditions RNA Viruses Risk and Prevention Viral Virology 721 721 1 05/15/23 20230515 NES 230515 2023 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Research findings on Liver Diseases and Conditions - Hepatitis C Virus are discussed in a new report. For more information on this research see: Repurposing of Drug Molecules From Fda Database Against Hepatitis C Virus E2 Protein Using Ensemble Docking Approach. [Extracted from the article]

For more information on this research see: Gender differences in prevalence of hepatitis C virus infection in Egypt: a systematic review and meta-analysis. Keywords: Digestive System Diseases and Conditions; Epidemiology; Flaviviridae Infections; Gastroenterology; Genetics; Health and Medicine; Hepacivirus; Hepatitis; Hepatitis C Virus; Hepatology; Infectious Diseases and Conditions; Liver Diseases and Conditions; Pediatrics; RNA Viruses; Risk and Prevention; Viral; Viral RNA; Virology EN Digestive System Diseases and Conditions Epidemiology Flaviviridae Infections Gastroenterology Genetics Health and Medicine Hepacivirus Hepatitis Hepatitis C Virus Hepatology Infectious Diseases and Conditions Liver Diseases and Conditions Pediatrics RNA Viruses Risk and Prevention Viral Viral RNA Virology 2023 MAR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Investigators discuss new findings in hepatitis C virus. [Extracted from the article]